白蛋白尿可预测IgA肾病肾脏事件
基于瑞典肾脏登记活检确诊原发性IgA肾病患者,分析尿白蛋白肌酐比(uACR)分层与主要不良肾脏事件(MAKE)的关联。中位随访5.5年,uACR 0.3-1.0 g/g患者MAKE风险已显著升高,且一年内uACR下降与更好肾脏结局相关,独立于基线uACR。
要点
- uACR 0.3-1.0 g/g的IgA肾病患者MAKE风险已显著增加,不应视为低危。
- 一年内uACR下降2倍与肾脏事件风险降低相关,独立于基线uACR。
- uACR可作为IgA肾病风险分层和治疗监测的实用指标。
核心结论
- uACR在0.3-1.0 g/g的IgA肾病患者存在显著的不良肾脏结局风险,该人群目前被认为CKD进展低危。
- uACR降低与更好的肾脏结局相关,独立于基线uACR。
研究设计与样本
- 来自瑞典肾脏登记活检确诊原发性IgA肾病患者,共纳入1269例(74%男性,中位53岁,平均eGFR 33 ml/min/1.73 m²,中位uACR 0.7 g/g)。
- 按uACR分类(<0.3、0.3-0.5、0.5-1.0、1.0-1.5、1.5-2.0、≥2.0 g/g)分析MAKE(KRT或eGFR下降>30%复合终点)发生情况。
- 在785例一年内有重复uACR测量的患者中探索uACR变化与肾脏事件风险的关系。
主要发现
- 中位随访5.5[2.8;9.2]年,发生667例MAKE、517例KRT、528例eGFR下降>30%。
- 与uACR<0.3 g/g相比,uACR 0.3-0.5 g/g的MAKE调整HR为1.56(95%CI 1.14-2.14),uACR≥2.0 g/g的MAKE调整HR为4.53(3.36-6.11)。
- KRT的调整HR范围1.39至4.65,eGFR下降>30%的调整HR范围1.76至3.47。
- 一年内uACR下降2倍者肾脏事件风险更低(HR范围0.47-0.49),uACR升高2倍者风险更高(HR范围1.18-2.56),独立于基线uACR。
关键数值与推荐
- uACR分类:<0.3、0.3-0.5、0.5-1.0、1.0-1.5、1.5-2.0、≥2.0 g/g。
- MAKE定义为KRT或eGFR下降>30%的复合终点。
- 与uACR<0.3 g/g相比,uACR 0.3-0.5 g/g的MAKE调整HR为1.56(95%CI 1.14-2.14),uACR≥2.0 g/g的MAKE调整HR为4.53(3.36-6.11)。
临床怎么用
- 对IgA肾病患者应重视uACR监测,即使uACR在0.3-1.0 g/g也需积极评估风险。
- 治疗中动态监测uACR变化,uACR下降提示肾脏结局改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: KDIGO recommends proteinuria <1 g/d as a treatment target in patients with immunoglobulin A nephropathy (IgAN) because of high risk of progression to kidney failure. However, long-term kidney outcomes in patients with low-grade proteinuria remain insufficiently studied. METHODS: We enrolled patients with biopsy-proven primary IgAN from the Swedish Renal Registry and analyzed associations between urine albumin-to-creatinine ratio (uACR, in categories <0.3, 0.3-0.5, 0.5-1.0, 1.0-1.5, 1.5-2.0, and ≥2.0 g/g) and the occurrence of major adverse kidney events [MAKE, a composite of kidney replacement therapy (KRT) and >30% decline in estimated glomerular filtration rate (eGFR)]. We also explored the risk of kidney events associated with change in uACR within a year. RESULTS: We included 1269 IgAN patients (74% men, median 53 years, mean eGFR 33 ml/min/1.73 m², median uACR 0.7 g/g). Over a median follow-up of 5.5 [2.8; 9.2] years, 667 MAKE and 517 KRT events occurred, and 528 patients experienced >30% eGFR decline. Compared with uACR < 0.3 g/g, any higher uACR category was strongly and incrementally associated with the risk of MAKE [adjusted hazard ratios (HR) ranging from 1.56 (95%CI 1.14-2.14) if uACR 0.3-0.5 g/g to 4.53 (3.36-6.11) if uACR ≥ 2.0 g/g], KRT (HR ranging from 1.39 to 4.65), and eGFR decline >30% (HR ranging from 1.76 to 3.47). In 785 patients who had repeated uACR measurements within a year, and compared with stable uACR, the risk of kidney events was lower if uACR decreased by 2-fold (HR ranging from 0.47 to 0.49), and higher if uACR increased by 2-fold (HR from 1.18 to 2.56), irrespective of baseline uACR. CONCLUSIONS: There is substantial risk of adverse kidney outcomes among patients with IgAN and uACR between 0.3 and 1.0 g/g, a population currently considered at low risk of CKD progression. Reduction in uACR is associated with better kidney outcomes, irrespective of baseline uACR.
引用
- Faucon AL, Lundberg S, Lando S, et al. Albuminuria predicts kidney events in IgA nephropathy. Nephrol Dial Transplant. 2025. PMID: 38688876. doi:10.1093/ndt/gfae085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。